2024
Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications
Gerke M, Jansen C, Bilen M. Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications. Cancers 2024, 16: 2280. PMID: 38927984, PMCID: PMC11201475, DOI: 10.3390/cancers16122280.Peer-Reviewed Original ResearchRenal cell carcinomaGU cancersProstate cancerBladder cancerGenitourinary (GU) cancersUtilization of liquid biopsyCastration-resistant prostate cancerDetect residual diseaseCirculating tumor DNATherapeutic response predictionCtDNA assaysResidual diseaseCtDNA analysisCell carcinomaTumor DNAGenitourinary cancersPrognostic informationClinical detection methodsTreatment responseGenomic alterationsLiquid biopsyClinical trialsTherapeutic implicationsCancerCtDNAAssociation of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
Goswamy R, Yildirim A, Wei M, Liu Y, Choi Y, Brown J, Nazha B, Master V, Martini D, Carthon B, Harris W, Kucuk O, Kissick H, Hartman C, McClintock G, Vo B, Jansen C, Zhuang T, Bilen M. Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2024, 42: e16527-e16527. DOI: 10.1200/jco.2024.42.16_suppl.e16527.Peer-Reviewed Original ResearchCD8 T cell infiltrationMetastatic renal cell carcinomaProgression-free survivalT cell infiltrationCD8 T cellsCheckpoint inhibitorsOverall survivalTyrosine kinase inhibitorsT cellsSystemic therapyTumor microenvironmentMetastatic renal cell carcinoma patientsAssociated with favorable clinical outcomesProgression-free survival outcomesRetrospective analysis of patientsCombination checkpoint inhibitorsIntratumoral T cellsProgression free survivalImproved overall survivalFavorable clinical outcomesWinship Cancer InstituteKaplan Meier analysisAnalysis of patientsRenal cell carcinomaCox proportional hazards modelsImpact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Patel J, Woo Y, Draper A, Jansen C, Carlisle J, Innominato P, Lévi F, Dhabaan L, Master V, Bilen M, Khan M, Lowe M, Kissick H, Buchwald Z, Qian D. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. Journal For ImmunoTherapy Of Cancer 2024, 12: e008011. PMID: 38531662, PMCID: PMC10966813, DOI: 10.1136/jitc-2023-008011.Peer-Reviewed Original ResearchConceptsInfusions of immune checkpoint inhibitorsMetastatic renal cell carcinomaProgression-free survivalOverall survivalRenal cell carcinomaCell carcinomaInternational Metastatic RCC Database Consortium risk scoreAssociated with longer progression-free survivalLung cancerGroup BGroup ATime of ICI initiationLonger progression-free survivalNon-small cell lung cancerMultivariable Cox proportional hazards regressionImmune checkpoint inhibitorsPretreatment lactate dehydrogenaseCell lung cancerCox proportional hazards regressionAdaptive immune responsesProportional hazards regressionMulticenter cohort analysisCheckpoint inhibitorsICI initiationMetastatic melanomaEstablished and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Jani Y, Jansen C, Gerke M, Bilen M. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma. Immunotherapy 2024, 16: 405-426. PMID: 38264827, DOI: 10.2217/imt-2023-0267.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaImmune checkpoint inhibitorsBiomarker of immunotherapyRisk of adverse eventsSignificant side effectsCheckpoint inhibitorsDevelopment of biomarkersAdverse eventsImmunotherapyTherapeutic efficacySide effectsPatientsClinical biomarkersPatient's diseaseTherapeutic biomarkersClinician's abilityBiomarkersCarcinomaPatient careImproving clinicians' abilityEfficacy
2023
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
Jansen C, Choi Y, Evans S, Greenwald R, Behnke J, Hartman C, Kissick H, Harik L, Bilen M. Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. Frontiers In Oncology 2023, 13: 1271255. PMID: 37860195, PMCID: PMC10582703, DOI: 10.3389/fonc.2023.1271255.Peer-Reviewed Original ResearchClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaTyrosine kinase inhibitor-targeted therapyResponse to systemic therapyWell-tolerated treatment optionCD8+T cell infiltrationCombination of immunotherapyResponse to nivolumabImmunotherapy to patientsMinimal adverse effectsVEGF-TKIDisease recurrenceCombination therapyTherapeutic regimensTherapeutic responseConsensus guidelinesTreatment optionsOptimal treatmentTumor tissuesRare typePatientsTherapy
2022
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
Carlisle J, Jansen C, Cardenas M, Sobierajska E, Reyes A, Greenwald R, Del Balzo L, Prokhnevska N, Kucuk O, Carthon B, Mullane P, Osunkoya A, Baumgarten D, Hosseinzadeh F, Wilkinson S, Lake R, Sowalsky A, Liu Y, Master V, Bilen M, Kissick H. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. Journal For ImmunoTherapy Of Cancer 2022, 10: e004803. PMID: 35863822, PMCID: PMC9310235, DOI: 10.1136/jitc-2022-004803.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCD8 T cellsCheckpoint therapyT cellsHLA-DRCell carcinomaClinical benefitActivation markers HLA-DRAdvanced renal cell carcinomaPre-existing immune responsesImmune responsePredictor of clinical benefitPeripheral T cell activationPeripheral blood of patientsFlow cytometryT-cell receptor (TCR) sequencingIntratumoral T cellsAntitumor immune responseMarkers HLA-DRAbundant T cellsProportion of CD4Cornerstone of treatmentT cell activationBlood of patientsPredicting therapeutic response
2021
Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
Martini D, Jansen C, Harik L, Evans S, Olsen T, Master V, Kissick H, Bilen M. Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers In Oncology 2021, 11: 793808. PMID: 34976834, PMCID: PMC8716393, DOI: 10.3389/fonc.2021.793808.Peer-Reviewed Original ResearchCD8+ T cellsResponse to treatmentT cellsLymphovascular invasionTranslocation-associated renal cell carcinomaFoci of lymphovascular invasionBiomarker of response to treatmentRadiographic response to treatmentFirst-line treatment optionFavorable response to treatmentIntratumoral immune infiltrationImmune checkpoint inhibitorsResponse to nivolumabRenal cell carcinomaPrimary tumor samplesYear old femalePresence of lymphocytesCheckpoint inhibitorsProgression-freeRare malignancyCell carcinomaPredictive biomarkersImmune infiltrationAggressive malignancyTreatment optionsA Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
Calagua C, Ficial M, Jansen C, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku A, Voznesensky O, Sykes D, Saylor P, Ye H, Signoretti S, Kissick H, Sowalsky A, Balk S, Einstein D. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical Cancer Research 2021, 27: 4836-4847. PMID: 34168052, PMCID: PMC8416924, DOI: 10.1158/1078-0432.ccr-21-0121.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCD8<sup>+</sup> T cellsImmune checkpoint inhibitorsPD-L1 expressionLocalized prostate cancerPrimary prostate cancerProstate cancerT cellsPD-L1Density of CD8<sup>+</sup> T cellsHigh-risk primary prostate cancerCD8 T-cell densityCharacterized tumor infiltrating lymphocytesLocalized prostate cancer casesPD-1<sup>+</sup> cellsTumor PD-L1 expressionUnique tumor immune microenvironmentPD-1 expressionTumor-infiltrating lymphocytesT-cell densityCD8 T cellsTumor immune microenvironmentTumor mutational burdenProstate cancer casesT-cell contentNeoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
Bilen M, Jiang J, Jansen C, Brown J, Harik L, Sekhar A, Kissick H, Maithel S, Kucuk O, Carthon B, Master V. Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. Frontiers In Oncology 2021, 10: 622134. PMID: 33598435, PMCID: PMC7882722, DOI: 10.3389/fonc.2020.622134.Peer-Reviewed Original ResearchRenal cell carcinomaMetastatic renal cell carcinomaMagnetic resonance imagingSurgical resectionNeoadjuvant settingCell carcinomaAdvanced renal cell carcinoma patientsLocally advanced renal cell carcinomaLeft renal cell carcinomaUnresectable renal cell carcinomaAdvanced renal cell carcinomaInvasion of adjacent structuresRenal cell carcinoma patientsNeoadjuvant systemic therapySecond-line settingSplenic flexure of colonTumor size reductionCell carcinoma patientsTail of pancreasReduced tumor growthAdjacent structuresTyrosine kinase c-MetCABOSUN trialPosterior abdominal wallTumor diameter
2019
Abstract 2700: CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche
Jansen C, Prokhnevska N, Master V, Carlisle J, Bilen M, Reyes A, Kissick H. Abstract 2700: CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche. Cancer Research 2019, 79: 2700-2700. DOI: 10.1158/1538-7445.am2019-2700.Peer-Reviewed Original ResearchCD8 T cell infiltrationT cell infiltrationTumor-infiltrating lymphocytesT cell responsesRenal cell carcinomaStem-like T cellsCancer-specific survivalT cellsRenal tumorsPatient survivalCD8 tumor-infiltrating lymphocytesPoor T-cell infiltrationDisease progressionAnti-tumor immune responseCD8 T cell responsesImmune responseTumor-infiltrating immune cellsFlow cytometryRenal cell carcinoma patientsCD8 T cellsStage III patientsIntensification of therapyRenal cell tumorsFollow-up timeEmory University Hospital
2018
Immunologic profile and prognostic significance of tumor-infiltrating lymphocytes in renal cell carcinoma.
Khan A, Jansen C, Wilkinson Carlisle J, Melnick K, Kim K, Hosseinzadeh F, Prokhnevska N, Bilen M, Master V, Kissick H. Immunologic profile and prognostic significance of tumor-infiltrating lymphocytes in renal cell carcinoma. Journal Of Clinical Oncology 2018, 36: 673-673. DOI: 10.1200/jco.2018.36.6_suppl.673.Peer-Reviewed Original ResearchUCLA Integrated Staging SystemTumor-infiltrating lymphocytesVenous tumor thrombusRenal cell carcinomaPrimary tumorCD8+Cell carcinomaPhenotype of tumor-infiltrating lymphocytesSignificance of tumor-infiltrating lymphocytesCo-inhibitory receptor expressionNon-metastatic primary tumorsHigher treatment failureCD8+ cellsIntegrated Staging SystemAssociated with recurrencePhenotype of primary tumorsMayo stageTIL levelsCD28+Tumor thrombusCo-stimulatoryEvaluate recurrencePrognostic factorsPrognostic scorePrognostic significance